Soleno Therapeutics (SLNO) announced certain preliminary unaudited financial and operational results for the three months ended June 30, 2025: Soleno expects its net revenue from the sales of VYKAT XR, for the three months ended June 30 to be between $31M and $33M. Soleno has determined net revenue for VYKAT XR with specific assumptions for Medicare/Medicaid rebates, chargebacks, copay assistance, returns reserve and prompt pay discounts. Soleno had approximately $293.8M in cash, cash equivalents and marketable securities as of June 30. Soleno received approximately 646 patient start forms from approximately 295 unique prescribers between March 26, the date of approval of its lead product candidate, VYKAT XR, and June 30. Soleno continued to have approximately $50M of debt outstanding under its loan and security agreement with Oxford Financing and its affiliates as of June 30.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics price target raised to $115 from $108 at Stifel
- Soleno Therapeutics highlights new data on VYKAT XR at United in Hope
- Soleno Therapeutics rumor highlighted in Betaville alert
- DoorDash, AMD upgraded: Wall Street’s top analyst calls
- Soleno Therapeutics initiated with a Buy at TD Cowen